As the global demand for advanced thyroid eye disease therapies surges in late 2025, pharmaceutical companies are shifting toward "local-for-local" manufacturing models. This involves producing biologics and specialized medical equipment closer to the end-markets in Europe and Asia-Pacific to avoid the tariffs and logistics delays that plagued the industry in previous years. By diversifying their supply chains and investing in regional production hubs, manufacturers are ensuring that life-saving medications remain available even during periods of global geopolitical instability or trade disputes.

The Thyroid Eye Disease Sector highlights that North America currently holds the largest share of the industry, but the Asia-Pacific region is experiencing the fastest growth. This is due to a massive increase in healthcare infrastructure in countries like Japan and South Korea, combined with rising awareness of autoimmune disorders. Regional governments are offering "expedited approval" pathways for orphan drugs, attracting global biotech firms to launch their newest TED therapies in these markets simultaneously with their U.S. debuts.

Furthermore, the 2025 focus on supply chain "resilience" has led to the development of better cold-chain technologies for the transport of monoclonal antibodies. Because these drugs are temperature-sensitive, "smart packaging" with real-time GPS and temperature tracking is now the industry standard. This ensures that every dose of medication arrives at the hospital or specialty clinic in perfect condition. As we move into 2026, the ability to maintain a stable and localized supply chain will be a major competitive advantage for the dominant players in the sector.

Frequently Asked Questions

Q. Why is there a focus on "local" manufacturing for these drugs?A. Biologics are complex to make and transport; producing them locally reduces the risk of the medicine being damaged during long international shipments and helps avoid price spikes from tariffs.

Q. Is thyroid eye disease more common in Asia than in the West?A. The prevalence is similar globally, but the "growth" in the Asian sector is higher right now because more people are gaining access to the advanced specialists who can diagnose and treat the condition.

explore our related reports